{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:53Z","timestamp":1786119473627,"version":"build-2736575974"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/meg.0b013e328335d95d","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T05:34:32Z","timestamp":1268890472000},"page":"583-590","source":"Crossref","is-referenced-by-count":8,"title":["Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis"],"prefix":"10.1097","volume":"22","author":[{"given":"Mohammad","family":"Yaghoobi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Padol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210207","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2036.2006.02747.x","article-title":"The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups","volume":"23","author":"Shapiro","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R2-13-20210207","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2036.2003.01423.x","article-title":"Non-erosive reflux disease (NERD) \u2013 acid reflux and symptom patterns","volume":"17","author":"Martinez","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R3-13-20210207","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":"Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial","volume":"96","author":"Richter","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R4-13-20210207","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","article-title":"Esomeprazole (40\u2009mg) compared with lansoprazole (30\u2009mg) in the treatment of erosive esophagitis","volume":"97","author":"Castell","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R5-13-20210207","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2005.02368.x","article-title":"A randomized comparative study of esomeprazole 40\u2009mg versus pantoprazole 40\u2009mg for healing erosive oesophagitis: the EXPO study","volume":"21","author":"Labenz","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-13-20210207","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":"Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-13-20210207","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1365-2036.1996.56198000.x","article-title":"Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole","volume":"10","author":"Mee","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl","key":"R8-13-20210207","first-page":"A230","article-title":"The impact of H. pylori status on healing of erosive and non-erosive GERD with esomeprazole: an analysis based on the ProGERD study initiative","volume":"17","author":"Malfertheiner","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R9-13-20210207","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","article-title":"Speed of healing and symptom relief in grade II\u2013IV gastroesophageal reflux disease: a meta-analysis","volume":"112","author":"Chiba","year":"1997","journal-title":"Gastroenterology"},{"key":"R10-13-20210207","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/gast.1996.v111.pm8698230","article-title":"The endoscopic assessment of esophagitis: a progress report on observer agreement","volume":"111","author":"Armstrong","year":"1996","journal-title":"Gastroenterology"},{"key":"R11-13-20210207","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/00365529309096057","article-title":"Interobserver variation in the endoscopic diagnosis of reflux oesophagitis","volume":"28","author":"Bytzer","year":"1993","journal-title":"Scand J Gastroenterol"},{"key":"R12-13-20210207","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0016-5085(88)90162-X","article-title":"Healing and relapse of severe peptic esophagitis after treatment with omeprazole","volume":"95","author":"Hetzel","year":"1988","journal-title":"Gastroenterology"},{"issue":"106","key":"R13-13-20210207","first-page":"26","article-title":"Contribution of endoscopy to gastroesophageal reflux disease","volume":"19","author":"Monnier","year":"1984","journal-title":"Scand J Gastroenterol"},{"key":"R14-13-20210207","first-page":"48","article-title":"Inter- and intra-observer variability of the Los Angeles classification: a reassessment","volume":"10","author":"Nasseri-Moghaddam","year":"2007","journal-title":"Arch Iran Med"},{"key":"R15-13-20210207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R16-13-20210207","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1046\/j.1365-2036.1997.00195.x","article-title":"Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole; comparison of 24-h intragastric and oesophageal pH","volume":"11","author":"Armbrecht","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-13-20210207","first-page":"2849","article-title":"Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease","volume":"96","author":"Armstrong","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R18-13-20210207","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1046\/j.1365-2036.2001.01089.x","article-title":"Comparable clinical efficacy and tolerability of 20\u2009mg pantoprazole and 20\u2009mg omeprazole in patients with grade I reflux oesophagitis","volume":"15","author":"Bardhan","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-13-20210207","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/gut.31.9.968","article-title":"Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations","volume":"31","author":"Bate","year":"1990","journal-title":"Gut"},{"key":"R20-13-20210207","first-page":"1749","article-title":"Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group","volume":"91","author":"Castell","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R21-13-20210207","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.3748\/wjg.v11.i20.3112","article-title":"Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis","volume":"11","author":"Chen","year":"2005","journal-title":"World J Gastroenterol"},{"key":"R22-13-20210207","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2036.1995.tb00437.x","article-title":"Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study","volume":"9","author":"Corinaldesi","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-13-20210207","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.31.5.509","article-title":"Double blind comparison of omeprazole (40\u2009mg od) versus cimetidine (400\u2009mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24\u2009h pH monitoring","volume":"31","author":"Dehn","year":"1990","journal-title":"Gut"},{"key":"R24-13-20210207","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2036.1999.00438.x","article-title":"Double-blind comparison (correction of Double-blind, placebo-controlled comparison) of rabeprazole 20\u2009mg versus omeprazole 20\u2009mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group","volume":"13","author":"Dekkers","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-13-20210207","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/003655200453566","article-title":"Rabeprazole, 20\u2009mg once daily or 10\u2009mg twice daily, is equivalent to omeprazole, 20\u2009mg once daily, in the healing of erosive gastrooesophageal reflux disease","volume":"35","author":"Delchier","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"R26-13-20210207","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1046\/j.1365-2036.1998.00381.x","article-title":"Pantoprazole 20\u2009mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis","volume":"12","author":"Dettmer","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-13-20210207","first-page":"245","article-title":"Pantoprazole versus lansoprazole in French patients with reflux esophagitis","volume":"25","author":"Dupas","year":"2001","journal-title":"Gastroenterol Clin Biol"},{"key":"R28-13-20210207","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1572-0241.2000.02233.x","article-title":"Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group","volume":"95","author":"Farley","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R29-13-20210207","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2036.2005.02339.x","article-title":"Efficacy of esomeprazole 40\u2009mg versus lansoprazole 30\u2009mg for healing moderate to severe erosive oesophagitis","volume":"21","author":"Fennerty","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-13-20210207","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00004836-200404000-00007","article-title":"40\u2009mg pantoprazole and 40\u2009mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms","volume":"38","author":"Gillessen","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"R31-13-20210207","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bmj.296.6615.89","article-title":"Omeprazole and ranitidine in treatment of reflux oesophagitis: double blindcomparative trial","volume":"296","author":"Havelund","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R32-13-20210207","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00044011-200222020-00004","article-title":"Evidence for therapeutic equivalence of lansoprazole 30\u2009mg and esomeprazole 40\u2009mg in the treatment of erosive esophagitis","volume":"222","author":"Howden","year":"2002","journal-title":"Clin Drug Invest"},{"key":"R33-13-20210207","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1046\/j.1365-2036.1999.00656.x","article-title":"Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group","volume":"13","author":"Jansen","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R34-13-20210207","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1046\/j.1440-1746.2002.02785.x","article-title":"Randomized comparative study of omeprazole and famotidine in reflux esophagitis","volume":"17","author":"Kawano","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R35-13-20210207","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(87)91726-0","article-title":"Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis","volume":"1","author":"Klinkenberg-Knol","year":"1987","journal-title":"Lancet"},{"key":"R36-13-20210207","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00004836-199504000-00005","article-title":"Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study","volume":"20","author":"Koop","year":"1995","journal-title":"J Clin Gastroenterol"},{"key":"R37-13-20210207","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000070201","article-title":"Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study","volume":"67","author":"Korner","year":"2003","journal-title":"Digestion"},{"key":"R38-13-20210207","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3109\/00365529509101589","article-title":"Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study","volume":"30","author":"Laursen","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"R39-13-20210207","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s10620-005-9071-3","article-title":"A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20\u2009mg) and standard-dose omeprazole (20\u2009mg) in patients with erosive esophagitis","volume":"51","author":"Lightdale","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R40-13-20210207","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1442-2050.2004.00424.x","article-title":"Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial","volume":"17","author":"Madan","year":"2004","journal-title":"Dis Esophagus"},{"key":"R41-13-20210207","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1442-2050.2002.00225.x","article-title":"Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate","volume":"15","author":"Meneghelli","year":"2002","journal-title":"Dis Esophagus"},{"key":"R42-13-20210207","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2036.1995.tb00388.x","article-title":"A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial","volume":"9","author":"Mossner","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"R43-13-20210207","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00042737-199611000-00013","article-title":"Lansoprazole 30\u2009mg versus omeprazole 40\u2009mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group","volume":"8","author":"Mulder","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R44-13-20210207","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.dld.2005.04.026","article-title":"Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20\u2009mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole","volume":"37","author":"Pace","year":"2005","journal-title":"Dig Liver Dis"},{"key":"R45-13-20210207","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00004836-199210000-00004","article-title":"Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine","volume":"15","author":"Bianchi Porro","year":"1992","journal-title":"J Clin Gastroenterol"},{"key":"R46-13-20210207","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/j.1572-0241.2000.03254.x","article-title":"Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group","volume":"95","author":"Richter","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R47-13-20210207","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2036.1993.tb00071.x","article-title":"Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis","volume":"7","author":"Robinson","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"R48-13-20210207","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2036.1995.tb00347.x","article-title":"A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group","volume":"9","author":"Robinson","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"R49-13-20210207","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3109\/00365528809090182","article-title":"The effect of omeprazole or ranitidine treatment on 24-h esophageal acidity in patients with reflux esophagitis","volume":"23","author":"Ruth","year":"1988","journal-title":"Scand J Gastroenterol"},{"key":"R50-13-20210207","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s10620-005-9062-4","article-title":"A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40\u2009mg) and omeprazole (20\u2009mg) for the treatment of erosive esophagitis","volume":"51","author":"Schmitt","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R51-13-20210207","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000083717","article-title":"Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis","volume":"70","author":"Schneider","year":"2004","journal-title":"Digestion"},{"key":"R52-13-20210207","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0016-5085(92)91790-B","article-title":"Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study","volume":"102","author":"Sontag","year":"1992","journal-title":"Gastroenterology"},{"key":"R53-13-20210207","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.0953-0673.1996.00397.x","article-title":"Efficacy and tolerability of pantoprazole 40 versus 80\u2009mg in patients with reflux oesophagitis","volume":"10","author":"Van Rensburg","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"R54-13-20210207","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/00042737-200108000-00006","article-title":"No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease","volume":"13","author":"Van Rensburg","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R55-13-20210207","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00042737-200012020-00011","article-title":"Efficacy and tolerability of 20\u2009mg pantoprazole versus 300\u2009mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study","volume":"12","author":"Van Zyl","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R56-13-20210207","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF01798351","article-title":"Omeprazole (40\u2009mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis","volume":"33","author":"Vantrappen","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R58-13-20210207","first-page":"63","article-title":"Endoscopic assessment of oesophagitis","volume":"1","author":"Armstrong","year":"1991","journal-title":"Gullet"},{"key":"R59-13-20210207","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.45.2.172","article-title":"Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification","volume":"45","author":"Lundell","year":"1999","journal-title":"Gut"},{"key":"R60-13-20210207","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/00365529409105366","article-title":"Symptoms and diseases severity in gastro-esophageal reflux disease","volume":"29","author":"Galmiche","year":"1994","journal-title":"Scan J Gastroenterol"},{"key":"R61-13-20210207","first-page":"848","article-title":"Natural history of gastro-esophageal reflux disease without esophagitis","volume":"32","author":"Pace","year":"1992","journal-title":"Gut"},{"key":"R63-13-20210207","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0149-2918(01)80087-4","article-title":"Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials","volume":"23","author":"Caro","year":"2001","journal-title":"Clin Ther"},{"key":"R64-13-20210207","doi-asserted-by":"crossref","first-page":"518","DOI":"10.7326\/0003-4819-140-7-200404060-00011","article-title":"Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics","volume":"140","author":"Numans","year":"2004","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MEG.0b013e328335d95d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:14:42Z","timestamp":1786040082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042737-201005000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0b013e328335d95d","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}